PTJ
DRNA

Paul Tudor Jones’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Paul Tudor Jones’s Portfolio DRNA Stock Details DRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-8,100
Closed -$302K – 2961
2021
Q2 		$302K Buy
+8,100
New +$248K 0.01% 1341

Other funds holding DRNA

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Paul Tudor Jones's DRNA Position: Q3 2021 in Review

Paul Tudor Jones sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q3 2021, closing a stake of 8,100 shares — an estimated $302K sold.

Paul Tudor Jones first reported a position in DRNA in Q2 2021 and held it in 1 quarter. The position peaked at $302K in Q2 2021. 173 funds tracked by Wall St. Rank hold DRNA as of Q3 2021.

  • Paul Tudor Jones reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q3 2021 after selling out during the quarter.
  • Paul Tudor Jones sold 8,100 Dicerna Pharmaceuticals, Inc. shares in Q3 2021, an estimated $302K.
  • Paul Tudor Jones first reported a position in Dicerna Pharmaceuticals, Inc. in Q2 2021 and held it in 1 quarter.
  • Paul Tudor Jones's Dicerna Pharmaceuticals, Inc. position peaked at $302K in Q2 2021.
  • 173 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q3 2021.

Based on Tudor Investment Corp's 13F filing for Q3 2021, filed 15 Nov 2021.